萬泰生物(603392.SH)6月9日股票成交額為50.18億 換手率達82.18%
格隆匯6月9日丨萬泰生物(603392.SH)發佈股票交易異常波動及風險提示公告,公司股票價格近期漲幅較大,自2020年4月29日至6月9日,已經連續上漲27個交易日(其中除首日外連續25個漲停),累計漲幅達到1557.14%。6月9日成交金額為50.18億,換手率達到82.18%。公司特別提醒投資者,注意二級市場交易風險。
公司市盈率水平較高,根據同花順iFinD數據顯示,截至2020年6月9日,公司滾動市盈率為263.00,遠高於醫藥製造業的行業滾動市盈率44.99;公司靜態市盈率為301.02,遠高於醫藥製造業的行業靜態市盈率69.22。
公司新冠檢測試劑目前僅有基於發光平台的新型冠狀病毒檢測試劑盒(雙抗原夾心法)取得國內醫療器械註冊證,且新冠檢測試劑銷售量佔公司總體收入比重不大,對公司財務狀況不會產生重大影響。
公司雙價宮頸癌疫苗(HPV2價)上市時間不長,疫苗銷售受市場推廣、消費者接受程度等多方面因素影響,疫苗銷售對於公司利潤的影響存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.